CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors
Con Panousis, Urmi Dhagat, Kirsten M Edwards, Veronika Rayzman, Matthew P Hardy, Hal Braley, Gail M Gauvreau, Timothy R Hercus, Steven Smith, Roma Sehmi, Laura McMillan, Mara Dottore, Barbara J McClure, Louis J Fabri, Gino Vairo, Angel F Lopez, Michael W Parker, Andrew D Nash, Nicholas J Wilson, Michael J Wilson Show all
MABS | TAYLOR & FRANCIS INC | Published : 2016
We thank CSL Limited Research staff (Recombinant Proteins Group, Antibody Technologies Group, Protein Technologies Group, Analytical Biochemistry Group), Karen Howie (McMaster University) and Kay Wycherley (WEHI Antibody Facility). This research was partly undertaken on the MX2 beamline at the Australian Synchrotron, Victoria, Australia and we thank the beamline staff for their assistance. This crystallography work was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) to M.W.P and A.F.L. and from the Australian Cancer Research Foundation to M.W.P. Funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute is acknowledged. U.D. and M.W.P. are NHMRC Post-doctoral and Research Fellows, respectively.